Medicare now must cover autoimmune drugs, limits insurer delays

What it does

This bill requires Medicare Part D prescription drug plans to cover all FDA-approved drugs for autoimmune diseases, hemophilia, and Von Willebrand disease starting in 2027, and prohibits insurers from requiring prior authorization for these drugs more than once per year (with narrow exceptions for short-term drugs, controlled substances, and drugs with FDA-mandated safety monitoring). The bill ensures Medicare beneficiaries with autoimmune and blood disorders have faster, more reliable access to their prescribed treatments.

Why we flagged it

The bill's operative mechanism is a straightforward mandate: Medicare Part D plans must cover specified drugs and limit prior authorization. It is a public-health access measure, not a tax provision, subsidy, or deregulation.

What the text implies

• Pharmaceutical manufacturers of autoimmune and blood disorder drugs may see increased volume and revenue as prior authorization barriers fall, though the bill does not directly subsidize or price-protect these drugs.
• Medicare Part D insurers (PDP sponsors) face higher claims costs and reduced ability to manage formulary costs through prior authorization gatekeeping, which may increase premiums or reduce insurer margins.
• The 12-month prior authorization window may create administrative burden for plans to track and enforce the once-per-year rule, requiring system changes.
• Beneficiaries with autoimmune diseases and blood disorders gain a protected class status in Medicare Part D, potentially creating a model for future drug-access mandates for other chronic conditions.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicare beneficiaries with autoimmune diseases and blood disorders gain guaranteed drug coverage and reduced administrative delays in accessing prescribed treatments. The prior authorization restriction directly reduces barriers that can delay or prevent access to medically necessary drugs.

Who stands to gain

• Medicare beneficiaries with autoimmune diseases and blood disorders (reduced out-of-pocket delays an
• Pharmaceutical manufacturers of autoimmune and blood disorder drugs (increased volume from reduced a

Named in the bill

Medicare Part D, PDP sponsors (prescription drug plan insurers), MA organizations (Medicare Advantage plans offering MA-PD), FDA, Social Security Act Section 1860D-4, Bipartisan Budget Act of 2018

Where it stands

5 cosponsors: 4 Democrats, 1 Republicans.

• Sep 18, 2025 — Introduced · Congress.gov: “Introduced in House”
• Sep 18, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

3 lobbying clients named this bill on 5 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $6,333,000 in lobbying spend. A filing names 43 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 61% of bills with at least one filing.

• American Medical Association — $5,643,000 on 2 filings
• Breakthrough T1d (formerly Known As Jdrf Intl.) — $510,000 on 2 filings
• American College of Rheumatology — $180,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.